Risk Stratification of Pediatric Patients With Neuroblastoma Using Volumetric Parameters of 18F-FDG and 18F-DOPA PET/CT

被引:42
作者
Liu, Chia-Ju [1 ]
Lu, Meng-Yao [2 ]
Liu, Yen-Lin [2 ,3 ,4 ,5 ]
Ko, Chi-Lun [6 ]
Ko, Kuan-Yin [1 ]
Tzen, Kai-Yuan [1 ]
Chang, Hsiu-Hao [2 ]
Yang, Yung-Li [2 ]
Jou, Shiann-Tarng [2 ]
Hsu, Wen-Ming [7 ]
Yen, Ruoh-Fang [1 ,8 ]
机构
[1] Natl Taiwan Univ Hosp, Dept Nucl Med, 7 Chung Shan South Rd, Taipei 100, Taiwan
[2] Natl Taiwan Univ Hosp, Dept Pediat, Taipei, Taiwan
[3] Taipei Med Univ Hosp, Dept Pediat, Taipei, Taiwan
[4] Natl Taiwan Univ, PhD Program Translat Med, Taipei, Taiwan
[5] Acad Sinica, Taipei, Taiwan
[6] Natl Taiwan Univ Hosp, Yun Lin Branch, Dept Nucl Med, Yunlin, Taiwan
[7] Natl Taiwan Univ Hosp, Dept Surg, 7 Chung Shan South Rd, Taipei 100, Taiwan
[8] Natl Taiwan Univ, Mol Imaging Ctr, Taipei, Taiwan
关键词
neuroblastoma; F-18-FDG; F-18-DOPA; volumetric parameters; risk stratification; POSITRON-EMISSION-TOMOGRAPHY; ONCOLOGY-GROUP EXPERIENCE; PROGNOSTIC-SIGNIFICANCE; CANCER; TUMORS; AMPLIFICATION; CHEMOTHERAPY; DIAGNOSIS; AGE; EXPRESSION;
D O I
10.1097/RLU.0000000000001529
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: This study determined the prognostic value of volumetric parameters derived from pretreatment F-18-FDG and F-18-DOPA PET/CTof neuroblastoma and their correlation with clinical and histopathologic features. Patients and Methods: A total of 25 children with neuroblastoma underwent pretreatment F-18-FDG and F-18-DOPA PET/CT within 4 weeks. The SUVmax of primary tumors on F-18-FDG and F-18-DOPA PET were recorded as SUVFDG and SUVDOPA, respectively. For volumetric parameters of primary tumors, 40% of SUVmax was used to generate volume of interest. If the 40% of SUVmax was below 2.5, an SUV threshold of 2.5 was used instead. Metabolic tumor volume (MTV), total lesion glycolysis (TLG), dopaminergic tumor volume (DTV), and total lesion F-18-DOPA activity (TLDA) were recorded as F-18-FDG and F-18-DOPA volumetric parameters. All indices were compared between groups distinguished by survival status and clinical features, including bone marrow involvement, lymph node metastasis, amplification of the MYCN oncogene, invasive features on anatomic images, and risk categories. The Kaplan-Meier method and log-rank test were used to compare the survival curves between groups. Results: The median follow-up period was 28.2 months. Nonsurvivors (20%) tended to have lower SUVDOPA, DTV, and TLDA (P = 0.05), and higher SUVFDG, MTV, and TLG (all P < 0.05). Lower F-18-DOPA uptake is associated with bone marrow and lymph node metastases (all P < 0.05). Higher F-18-FDG uptake is associated with MYCN amplification (all P < 0.05) and anatomic invasive features of tumors such as vascular encasement or adjacent organ invasion (TLG, P = 0.05). Only volumetric indices (DTV, TLDA, MTV, and TLG) significantly differed among risk groups (all P < 0.05). Conclusions: Pretherapeutic F-18-DOPA and F-18-FDG PET provided complementary information, and both can be served for risk stratification. Volumetric indices of F-18-DOPA and F-18-FDG PET correlate more highly with risk grouping.
引用
收藏
页码:E142 / E148
页数:7
相关论文
共 49 条
[1]   Metabolic (PET) and receptor (SPET) imaging of well- and less well-differentiated tumours: Comparison with the expression of the Ki-67 antigen [J].
Adams, S ;
Baum, RP ;
Hertel, A ;
Schumm-Drager, PM ;
Usadel, KH ;
Hor, G .
NUCLEAR MEDICINE COMMUNICATIONS, 1998, 19 (07) :641-647
[2]   Significance of MYCN Amplification in International Neuroblastoma Staging System Stage 1 and 2 Neuroblastoma: A Report From the International Neuroblastoma Risk Group Database [J].
Bagatell, Rochelle ;
Beck-Popovic, Maja ;
London, Wendy B. ;
Zhang, Yang ;
Pearson, Andrew D. J. ;
Matthay, Katherine K. ;
Monclair, Tom ;
Ambros, Peter F. ;
Cohn, Susan L. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (03) :365-370
[3]   Outcome after Reduced Chemotherapy for Intermediate-Risk Neuroblastoma. [J].
Baker, David L. ;
Schmidt, Mary L. ;
Cohn, Susan L. ;
Maris, John M. ;
London, Wendy B. ;
Buxton, Allen ;
Stram, Daniel ;
Castleberry, Robert P. ;
Shimada, Hiroyuki ;
Sandler, Anthony ;
Shamberger, Robert C. ;
Look, A. Thomas ;
Reynolds, C. Patrick ;
Seeger, Robert C. ;
Matthay, Katherine K. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (14) :1313-1323
[4]   123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma [J].
Bleeker, Gitta ;
Tytgat, Godelieve A. M. ;
Adam, Judit A. ;
Carona, Huib N. ;
Kremer, Leontien C. M. ;
Hooft, Lotty ;
van Dalen, Elvira C. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (09)
[5]   MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis [J].
Bleeker, Gitta ;
van Eck-Smit, Berthe L. ;
Zwinderman, Koos H. ;
Versteeg, Rogier ;
van Noesel, Max M. ;
Kam, Boen L. ;
Kaspers, Gertjan J. ;
van Schie, Annelies ;
Kreissman, Susan G. ;
Yanik, Gregory ;
Hero, Barbara ;
Schmidt, Matthias ;
Laureys, Genevieve ;
Lambert, Bieke ;
Ora, Ingrid ;
Schulte, Johannes H. ;
Caron, Huib N. ;
Tytgat, Godelieve A. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 (02) :222-230
[6]   Cholinergic switch associated with morphological differentiation in neuroblastoma [J].
Bourdeaut, Franck ;
Janoueix-Lerosey, Isabelle ;
Lucchesi, Carlo ;
Parls, Regine ;
Ribeiro, Agnes ;
de Pontual, Loic ;
Amie, Jeanne ;
Lyonnet, Stanislas ;
Pierron, Gaealle ;
Michon, Jean ;
Peuchmaur, Michel ;
Delattre, Olivier .
JOURNAL OF PATHOLOGY, 2009, 219 (04) :463-472
[7]   AMPLIFICATION OF N-MYC IN UNTREATED HUMAN NEUROBLASTOMAS CORRELATES WITH ADVANCED DISEASE STAGE [J].
BRODEUR, GM ;
SEEGER, RC ;
SCHWAB, M ;
VARMUS, HE ;
BISHOP, JM .
SCIENCE, 1984, 224 (4653) :1121-1124
[8]   REVISIONS OF THE INTERNATIONAL CRITERIA FOR NEUROBLASTOMA DIAGNOSIS, STAGING, AND RESPONSE TO TREATMENT [J].
BRODEUR, GM ;
PRITCHARD, J ;
BERTHOLD, F ;
CARLSEN, NLT ;
CASTEL, V ;
CASTLEBERRY, RP ;
DEBERNARDI, B ;
EVANS, AE ;
FAVROT, M ;
HEDBORG, F ;
KANEKO, M ;
KEMSHEAD, J ;
LAMPERT, F ;
LEE, REJ ;
LOOK, AT ;
PEARSON, ADJ ;
PHILIP, T ;
ROALD, B ;
SAWADA, T ;
SEEGER, RC ;
TSUCHIDA, Y ;
VOUTE, PA .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (08) :1466-1477
[9]   Neuroblastoma: Biological insights into a clinical enigma [J].
Brodeur, GM .
NATURE REVIEWS CANCER, 2003, 3 (03) :203-216
[10]   THE PEDIATRIC-ONCOLOGY-GROUP EXPERIENCE WITH THE INTERNATIONAL STAGING SYSTEM CRITERIA FOR NEUROBLASTOMA [J].
CASTLEBERRY, RP ;
SHUSTER, JJ ;
SMITH, EI .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (11) :2378-2381